BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

302.17M

Vuru Grade

23.50/100

Current Price

$4.10
-0.29 (-6.61%)

Company Metrics

  • P/E 0
  • P/S 12.84
  • P/B 24.12
  • EPS -0.98
  • Cash ROIC -251.78%
  • Cash Ratio 0.80
  • Dividend 0 / N/A %
  • Avg. Vol. 959,452.00
  • Shares 73.70M
  • Market Cap. 302.17M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Current BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT Means Stock Is Worth ...
Review Fortune - 12 hours ago
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) up 1.86% for the past 5 days, is under coverage of 9 analysts who collectively assign a hold rating on stock.
Zacks Pegs BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) EPS At $-0.22 For ... - RealistInvestor.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Announces An EPS Of $-0.22 On ... - Equities Focus
Here's the Buzz Behind BioCryst Pharmaceuticals, Inc.'s 27% Gain in July
Motley Fool - Aug 11, 2016
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotechnology company primarily focused on small-molecule drugs that block enzymes associated with disease development, leaped 27% in July, according to data from S&P Global Market ...
Notable Analyst Views: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), 3D ... - Review Fortune
BioCryst Pharmaceuticals Inc. (BCRX) Insider Thomas R. Staab II Sells 14577 Shares - BBNS
Biocryst Pharmaceuticals Inc (BCRX): Billionaire David E. Shaw's Fund ...
Insider Monkey (blog) - Aug 23, 2016
Billionaire David E. Shaw's D E Shaw has recently filed a Form 13G with the US SEC in which it reported holding 3.74 million common shares of Biocryst Pharmaceuticals Inc (NASDAQ:BCRX), which account for 5.1% of the company's outstanding stock.
Biocryst Pharmaceuticals Inc Has Another Bullish Trade, D. E. Shaw & Co Bought ... - Press Telegraph
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports EBIT Of $-12.13 - Enterprise Leader
What Analysts say about BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)?
Review Fortune - Aug 15, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) received a stock rating upgrade from Piper Jaffray on Aug-12-16. In a note to investors, the firm issued a Overweight rating an.
Most Recent analysts Ratings: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - News Oracle
Active Biotech Stock News: BioCryst Pharmaceuticals, Inc. (BCRX), Gilead ... - Zergwatch
Biocryst Pharmaceuticals Inc (BCRX): Baker Bros. Advisors Unloads Nearly 4 ...
Insider Monkey (blog) - Aug 17, 2016
Julian Baker and Felix Baker's Baker Bros. Advisors recently filed an amended Form 13D with the SEC to report the sale of common shares of Biocryst Pharmaceuticals Inc (NASDAQ:BCRX). Its stake in the company now consists of 11.06 million shares, which ...
Analyst Ratings Summary To Observe: Allegheny Technologies Incorporated (NYSE ... - Review Fortune
Analysts See BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reporting EPS Of $-0.22 - RealistInvestor.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Earns Consensus Hold Rating
Review Fortune - Aug 10, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) up 31.3% for the past 5 days, is under coverage of 9 analysts who collectively assign a hold rating on stock.
Price Target Analysis: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - News Oracle
Stocks inside Analysts Limelight: Amarin (NASDAQ:AMRN) , BioCryst ... - Street Updates
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Updated Analyst Ratings
Review Fortune - Aug 12, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) up 25.75% for the past 5 days, is under coverage of 9 analysts who collectively assign a hold rating on stock.
Analyst Update: InvenSense Inc, BioCryst Pharmaceuticals, Inc., and Alibaba ... - Schaeffers Research (blog)
Biotech stocks for your portfolio: BioMarin Pharmaceutical Inc. (BMRN ... - Zergwatch
BioCryst Pharmaceuticals Inc. (BCRX) to Release Quarterly Earnings on Thursday
The Cerbat Gem - Aug 3, 2016
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is scheduled to announce its earnings results before the market opens on Thursday, August 4th.
BioCryst Pharmaceuticals Inc. (BCRX) Price Target Raised to $3.00 at Jefferies ... - Community Financial News
BioCryst Pharmaceuticals Inc. (BCRX) Drops 7.42% on August 16
Equities.com - Aug 17, 2016
BioCryst Pharmaceuticals Inc. (BCRX) was one of the Russell 2000's biggest losers for Tuesday August 16 as the stock slid 7.42% to $4.37, a loss of $-0.35 per share.
Biotech news that matter for investors: BioCryst Pharmaceuticals, Inc. (NASDAQ ...
The Voice Registrar - Aug 24, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) share price rose to $4.64 each in the last trading day compared to a prev close of $4.45.